Vectura is an industry-leading inhaled airways disease focused business with proprietary formulations and devices.

Focusing our core capabilities with a balanced approach to building wholly-owned specialist capability

Current sustainable cash flows
NOVEL PATENTED MOLECULE AND DEVICE PARTNERING
Current sustainable cash flows
GENERIC/ANALOGUE MOLECULE AND DEVICE PARTNERING
Future value capture
WHOLLY-OWNED SPECIALIST ASSETS
Uniquely integrated inhaled drug delivery platform
Formulation
Development
Devices

Vectura has a range of enabling formulations, analytics, process development and pre-commercial scale manufacturing capabilities which are aligned to its range of device technologies. This uniquely integrated inhaled drug delivery platform enables the development of inhalation products and in particular for the treatment of airways diseases.

Read more on our strategy


Industry-leading formulation and device technologies

Dry powder inhalers (DPIs)

GyroHaler®

Lever-operated

Open-inhale-close

Unit-dose

Pressurised metered dose inhalers (pMDI)

Dose-indicating MDI actuator

Smart nebuliser technology

AKITA® JET

FOX®

Read more on our technologies


Our highly skilled employees are committed to achieving our purpose of transforming the lives of airways disease patients

c.450 employees

Corporate office

London, UK

Inhalation development activity

Chippenham and Cambridge, UK
Muttenz, Switzerland
Gauting, Germany

Oral manufacturing site

Lyon, France

Contact us


Uniquely integrated inhaled drug delivery platform

Strong IP portfolio
  • 151 live patent families with over 20 licensees

Read more about our portfolio